Visit Website →
← Back to blog

LIMS Integration for PGx Labs: Why PDFs Fail at Decision Support

October 16, 2026
LIMS Integration for PGx Labs: Why PDFs Fail at Decision Support

Connect your LIMS to your PGx platform through a standards-first, middleware-enabled pipeline: HL7v2 LRI messages (plus FHIR where your EHR supports it), diplotype and phenotype mapping tables defined up front using LOINC and CPIC, and a validation cycle of a few weeks. Structured observations, not PDFs, are what make clinical decision support reliable and scalable.

TL;DR:

  • Use middleware to convert VCF or XML into HL7v2 LRI or FHIR; keep HL7v2 for current EHRs and add FHIR where supported.
  • Define versioned genotype to diplotype and phenotype tables, including activity scores and LOINC codes, before building middleware, and keep PGx classification separate from ACMG.
  • Return diplotypes, phenotypes, therapeutic implications, and matching patient and sample identifiers as structured fields rather than PDFs, so EHRs can act during prescribing.
  • Allow a few weeks for validation, covering conversion unit tests, sandbox EHR ingestion, medication order alert checks, clinician acceptance testing, and audit log review.
  • Use genomic indicators to trigger mostly passive alerts, reserving interruptive warnings for gene and drug pairs where CPIC recommends an alternative.
SignalPGx
Make PGx Results Ready for EHRs
SignalPGx turns genotype and medication data into physician-reviewed reports and supports EHR integration through HL7/FHIR standards.
Explore SignalPGx

Table of Contents

Which standards and vocabularies should anchor your LIMS and PGx integration?

Start with the standards your receiving systems already speak, then layer in the newer ones.

  • HL7v2 LRI structures genomic data in OBX segments, so HL7v2 LRI and FHIR are the primary standards for exchanging clinical genomic data between laboratories and EHRs.
  • FHIR Genomics and Genomics Operations offer API-driven access and phenotype operations, though some operations were still maturing at publication. Plan to support both formats.
  • LOINC supplies answer codes for PGx phenotypes, and CPIC guidelines define the clinical reporting criteria behind them.

Many production EHRs still rely on HL7v2 interfaces even as FHIR adoption grows, so a dual-format design protects you from rework.

What does the data flow from LIMS to PGx platform and back look like?

Data moves in both directions. Your LIMS sends sample identifiers and either raw sequencing files (FASTQ) or variant calls (VCF) to the analysis pipeline. Some labs send annotated XML or VCF-derived files instead. Tools such as PharmCAT annotate VCF files with haplotypes and diplotypes for CPIC genes and support batch automation.

The platform then returns results you must preserve as discrete data:

  • Diplotypes and the phenotypes or activity scores derived from them.
  • Therapeutic implications tied to each gene–drug pair.
  • Sample and patient identifiers that reconcile with the originating LIMS record.

Resist the PDF shortcut. The main hurdle in PGx exchange is moving from unstructured PDF results to structured data that EHRs can parse and act on at prescribing.

Which integration architecture and middleware patterns work best?

Most successful implementations place a translation layer between the lab and the EHR. Epic-based integrations frequently use a Linux-based intermediary to convert raw laboratory results into the HL7 or FHIR formats the EHR expects and to validate genomic payloads the EHR cannot handle directly.

  • Convert VCF or XML into HL7v2 LRI or FHIR in the middleware, validate message structure, then hand off to your interface engine.
  • Reuse open-source converters and modular extractors (the vcf2fhir and hl7v2GenomicsExtractor patterns) instead of writing custom parsers.
  • Decide deliberately where normalization lives: the PGx platform, the middleware or the EHR. Centralizing mapping in middleware makes EHR-specific tailoring easier to maintain.

If you are weighing legacy and modern interfaces, this primer on HL7 versus FHIR covers the tradeoffs from a developer's view.

Pro Tip: Keep mapping logic in a versioned location. When a guideline or code changes, update it centrally instead of across multiple systems.

What mapping and terminology must your lab define before go-live?

Mapping is where most schedules slip, so assign owners early. Our guide to genotype to phenotype translation goes deeper on the reporting side. At minimum, define:

  • Genotype→diplotype→phenotype translation tables, including star alleles and activity scores, versioned alongside the guideline releases they reflect.
  • LOINC PGx answer codes for each phenotype, with CPIC citations carried as RelatedArtifact entries so CDS can point back to the source recommendation.
  • Machine-readable therapeutic implication objects: the HL7 Genomics Reporting Implementation Guide models these within DiagnosticReport structures, and equivalent structured OBX components serve HL7v2.
  • A variant classification framework for PGx that is distinct from ACMG pathogenic classifications, as CPIC advises.

How long does validation take, and what should you test?

Plan for a few weeks of validation, depending on panel size and EHR complexity. EHR modules may also need specific interface configuration, and the Epic genomic module experience shows integration is rarely plug-and-play. Work through these phases in order:

  1. Unit tests on each conversion step, including schema validation of every outbound message.
  2. End-to-end sandbox ingestion of HL7v2 or FHIR messages into a non-production EHR.
  3. CDS trigger validation using representative medication orders.
  4. User acceptance testing with clinicians and pharmacists.
  5. Audit trail and message log verification.

Set revalidation triggers so any change to panel content, CPIC references or LOINC mappings sends you back through testing.

How do structured PGx results drive clinical decision support?

Structured results let the EHR act at the moment of prescribing. Design for restraint, because automating integration requires defining which gene–drug situations should trigger alerts to avoid alert fatigue.

  • Use genomic indicators, meaning summary phenotype or activity score values, as CDS triggers. Rules stay simpler and cheaper to maintain.
  • Favor passive in-line alerts for most gene–drug pairs, and reserve interruptive alerts for high-risk pairs where CPIC recommends an alternative.
  • Work with pharmacy informatics to map medication codes and refine alert wording over several iterations.

Our drug–gene interactions reference can help you decide which pairs belong in each tier.

Pro Tip: Launch with one gene–drug pair, prove the alert behaves as intended, then expand. Our walkthrough on mapping one pair in FHIR first shows how.

Structured PGx result passing through an alert rule

What does a practical implementation checklist look like for lab operators?

Follow this order from planning through maintenance, and see our lab operator's playbook for the broader launch picture.

  1. Preflight: confirm panel genes, select LOINC and CPIC references, name mapping owners, and review security and HIPAA requirements, including how patient data is segregated if you run multiple client accounts.
  2. Integration: deploy middleware, run conversion pipelines, and verify HL7v2 or FHIR messages in the sandbox.
  3. Validation: test CDS triggers against test charts and confirm audit trails capture every message.
  4. Training: brief lab staff and clinicians on how results now arrive and display.
  5. Go-live: monitor message queues and logs closely during the first weeks.
  6. Maintenance: schedule living reanalysis and version updates, and keep a clinician feedback loop open.

Pro Tip: Budget for scale from day one. Queue monitoring and mapping versioning that feel excessive at low volumes can help prevent outages as testing scales.

What I have learned from the lab informatics bench

Two blockers show up again and again: nobody owns the mapping tables, and CDS gets too little sandbox testing before go-live. Fix both early. Build the mapping first, then run small pilots and iterate. Put lab, pharmacy and IT in one room before a single message is built, because the hardest problems are organizational, not technical.

— Tarek

How we support labs that want integration-ready PGx reporting

If you would rather not build this stack from scratch, our team offers white-label PGx reporting with HL7/FHIR integration, evidence-graded reports, living reanalysis that updates recommendations as guidelines evolve, and medical-director review with a full audit trail. Labs typically deploy their own branded service in 5 to 7 days.

SignalPGx

We also provide Discovery & Strategy, System Design, and Deployment & Integration services, so our engineers can handle mapping, middleware and EHR connectivity alongside you. Review the White-Label PGx Reporting plans and contact us for a demo or an integration engagement.

FAQ

How long does a LIMS to PGx integration usually take?

Setup and validation typically take a few weeks, depending on workflow complexity. Panel size, EHR configuration and the number of CDS rules are the main drivers.

Do I need FHIR, or is HL7v2 enough?

HL7v2 LRI is enough for many EHRs today, since production systems still rely heavily on HL7v2 interfaces. Supporting FHIR as well prepares you for modern, API-driven applications.

Why not just send PGx results as PDFs?

PDFs cannot trigger decision support, so clinicians must find and interpret results manually. Structured diplotypes and phenotypes let the EHR alert at the moment of prescribing and keep an auditable record.

What is the most common reason PGx integrations stall?

Undefined mapping ownership is the most common cause. Without agreed diplotype, phenotype and LOINC tables, middleware and CDS rules cannot be finalized.

Sources